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INTRODUCTION
Systemic lupus erythematosus (SLE) is a chronic in-
fl ammatory disorder of connective tissue characterized 
by the presence of autoreactive B- and T-lymphocytes 
responsible for the production of a heterogeneous 
spectrum of autoantibodies (1). Lupus nephritis (LN) 
is a serious complication, which aff ects up to 60% of 
adults with SLE, contributing as a signifi cant cause 
of morbidity and mortality (2). Despite better under-
standing of the pathophysiological process and new, 
more aggressive treatment protocols, the incidence 
of end-stage kidney disease (ESKD) has increased 
signifi cantly between 1982 and 2004 from 1.16 cases 
per million person-years in 1982 to 3.08 and 4.9 cases 
per million person-years in 1995 and 2004 (3). Th us, 
choosing the optimal modality of renal replacement 
therapy (RRT) is of great importance (4,5). Although 
the 5- and 10-year survival rates were similar in pa-
tients treated with hemodialysis (HD) and peritoneal 
dialysis (PD), kidney transplantation (KT) was shown 
to be highly superior (6). When compared to dialysis, 
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KT achieves better survival rate and better quality of 
life, at the same time reducing the SLE activity (7-9). 
Over the course of time, since transplantation started 
in the 1950s until the 1990s, the 5-year survival rate 
in LN patients aft er transplant increased from less 
than 50% to more than 93% (10). Although clinical 
outcome aft er KT in patients with LN has lately been 
shown to be comparable to other causes of ESKD (for 
example, diabetes mellitus and arterial hypertension), 
a controversy still exists. Infection, recurrent disease, 
acute and chronic rejection and thrombosis are some 
of the risks factors leading to graft  failure in SLE pa-
tients (11). Furthermore, SLE patients have a higher 
rate of cardiovascular disease, which is a common 
cause of death aft er transplant (2,12). Th e aim of this 
study was to evaluate the outcomes of KT in patients 
with SLE and discuss future management options for 
improved survival in this patient category. 
PATIENTS AND METHODS
A total of 12 patients having undergone KT during the 
period from February 2007 until October 2013 were 
included in this retrospective observational study. We 
investigated disease duration, type of RRT and dialy-
sis vintage, comorbidities, induction and maintenance 
therapies, and blood values for signs of SLE activity or 
decreased graft  function. 
RESULTS
Patient characteristics
Th ere were eight female (66.7%) and four male 
(33.3%) patients, median age 37 (18-56) years. Th e av-
erage duration of RRT before transplant was 7 (1-18) 
years. One patient had been previously transplanted. 
His fi rst graft  was lost due to LN recurrence in 1991, 
two years aft er transplantation. Comorbidities were 
primarily cardiovascular.
All patients received kidney from deceased donors. 
Eleven (91.7%) patients showed no clinical or serolog-
ic signs of SLE activity at the time of transplantation; 
total complement activity (CH50), as well as the levels 
of complement proteins C3 and C4 were normal, an-
ti-dsDNA and antinuclear antibodies (ANA) were not 
detected by indirect immunofl uorescence technique 
prior to transplantation. Antiphospholipid (APS) an-
tibodies were also negative. Immunological matching 
was favorable. Maintenance immunosuppressive ther-
apy included calcineurin inhibitor, mycophenolic acid 
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Patient survival
One patient died 4 months aft er the transplantation 
from neurological complications. She had no clinical 
signs of SLE at the time of transplantation, however, 
elevated anti-dsDNA antibodies, ANA, PRA (80%) 
and low plaelet count were recorded before transplan-
tation. Aft er consulting the immunologist who fol-
lowed-up the patient, she underwent transplantation. 
Induction therapy included Th ymoglobulin. Graft 
function was immediate, but the patient developed 
severe acute humoral rejection on day 13 post-trans-
plant. Aft er intensifying immunosuppressive therapy 
with 5 boluses of corticosteroids combined with 4 
plasma-exchanges (one plasma volume, albumins as 
replacement fl uid) on alternate days, her laborato-
ry values stabilized and she was discharged from the 
hospital. Four months later, she went into a coma aft er 
a short period of febrility and died shortly thereaft er. 
Her family refused autopsy.
Graft  survival
Out of 12 patients, 11 (91.7%) are still alive, eight 
(66.7%) with stable graft  function. Median graft  sur-
vival for the whole patient population was 41 (0-93) 
months. In those with stable graft  function, median 
survival was 61 (22-93) months, in three patients lon-
ger than fi ve years. Th e causes of graft  loss included 
death with a functioning graft , pseudoaneurysm of the 
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renal graft  artery, thrombosis of the renal graft  vein, 
and severe biopsy confi rmed acute allograft  rejection 
accompanied with sepsis. All patients with allograft  
loss had 2 or more comorbidities, one being hyperten-
sion. Th e others were avascular necrosis of the femoral 
head and triple (aortic, mitral and tricuspid) valvular 
insuffi  ciency in the patient with acute rejection, epi-
lepsy in the patient with venous thrombosis, and atrial 
fi brillation in the patient with the graft  artery pseudo-
aneurysm. Disease duration, defi ned as the time from 
diagnosis until the year of transplant, was shorter in 
the group who lost their allograft , i.e. mean 11.7 years 
compared with 12.7 years in those with stable graft  
function (n=8) (not signifi cant). Two (16.7%) patients 
experienced thrombotic events, one of the graft  artery, 
which led to explantation, and the other of the deep 
veins of the leg and this patient has a functioning graft  
today. Serological screening for APS antibodies prior 
to transplantation was negative in both patients. Th ere 
was no correlation between immunological matching 
and transplant outcome. 
Post-transplant complications
Early post-transplant period was complicated with 
secondary wound healing in two patients, lymphor-
rhea in one patient, and development of lymphocele 
followed by obstructive uropathy and hydronephrosis 
of the graft  in one patient. Major complications that 
arose aft er transplantation were cardiovascular and 
included atrial fi brillation in one patient, valvular in-
suffi  ciency, graft  artery pseudoaneurysm, graft  vein 
thrombosis and deep vein thrombosis. Also, one pa-
tient developed new-onset diabetes aft er transplanta-
tion (NODAT). One patient developed urinary blad-
der carcinoma and was switched from cyclosporine to 
sirolimus. One year later, the graft  function deterio-
rated requiring graft  biopsy. Biopsy was complicated 
with perirenal hematoma measuring 15x8 cm. Th e 
histopathologic fi nding indicated LN recurrence in 
the allograft  although she had been serologically neg-
ative for 15 years.
One patient developed cytomegalovirus infection, 
which was successfully treated with valgancyclovir. 
Hematologic complications included two cases of leu-
kopenia that demanded use of fi lgrastim, and eryth-
rocytosis in one patient. Acute rejection was recorded 
in two patients. One had already described acute hu-
moral rejection, and the other patient experienced two 
episodes of acute cellular allograft  rejection success-
fully treated with steroid boluses. Two patients had 
problems with tendons. One developed rupture of the 
Achilles tendon, and the other had severe tendinitis 
aft er the use of ciprofl oxacin, which was immediately 
stopped. It is interesting to mention our female patient 
who underwent a dual kidney transplant from a pedi-
atric donor in 2002, although she was not included in 
the study. She was diagnosed with SLE in 1997 aft er a 
biopsy taken during an episode of preeclampsia. Aft er 
transplantation, the graft  function was immediate al-
though ultrasound showed mild dilatation of the ure-
ter and pyelon on one side. Th at kidney was explanted 
in 2009 due to recurrent urinary tract infections. His-
topathologic evaluation showed signs of necrosis of 
ureter epithelium, urinary leak and hydronephrosis. 
Th e other kidney is functioning well and her lab values 
are satisfactory. She has had no other manifestation of 
SLE since the biopsy in 1997.
DISCUSSION
Systemic lupus erythematosus is a chronic multi-
system disorder aff ecting many organs, with renal 
involvement being the most important predictor of 
mortality (2). As this specifi c population of patients 
tends to develop ESKD at a much younger age, choos-
ing the individual RRT protocol is a priority, with KT 
being the ultimate goal (4,5,13). Th e majority of stud-
ies that compared diff erent renal replacement modal-
ities demonstrated that KT off ered better outcomes 
and lower complication rates in comparison with oth-
er treatment modalities (6,14-16). Although living re-
lated KT (LRKT) was shown to give better results than 
graft s from deceased donors, other studies revealed 
that graft s from deceased donors had similar out-
comes to LRKT (17-19). Preemptive KT has also been 
pointed out as a treatment option with superior sur-
vival outcomes. It off ered lower risk of death and re-
jection with a signifi cantly greater chance of getting an 
allograft  from a living donor (20). However, when dis-
cussing preemptive KT we should clearly state that not 
all SLE patients are eligible for this kind of approach. 
Current recommendations state that patients who 
progress to ESKD as a result of LN worsening or newly 
diagnosed SLE patients with rapidly progressive renal 
disease should start HD treatment for 3 to 6 months 
prior to proceeding to KT. Th e rationale behind this 
is to achieve overall remission of SLE activity before 
KT, as HD is believed to have a ‘burn-out’ eff ect on 
the disease. Furthermore, it seems that some patients 
with aggressive forms of rapid progressive glomeru-
lonephritis recover their renal function aft er starting 
HD (3,21). Even though all our recipients received 
kidneys from deceased donors, 66.7% have completely 
satisfying graft  function with median graft  survival of 
41 (0-93) months for the whole patient population. It 
has been shown that greater Charlson comorbidity in-
dex and immunizing events prior to KT (higher panel 
reactive antibody (PRA) levels, previous transplanta-
tions, multiple blood transfusions and pre-transplant 
pregnancy) have been associated with worse outcomes 
(19). 
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High PRA levels were associated with increased loss of 
allograft , but had no eff ect on mortality (14). Accord-
ing to some studies, the level of anti-dsDNA antibod-
ies are not a reliable serological parameter for disease 
activity in transplanted patients or a good predictor of 
outcome. However, low complement levels has been 
shown to correlate with a higher risk of allograft  loss 
(15,16,22,23). In a study dividing SLE patients into 
low complement and normal complement groups, the 
graft  survival was 78.6% in the normal complement 
group and 30% in the low complement group aft er 
96 months of follow up. Th e authors found a connec-
tion between low complement, proteinuria and poor-
er allograft  survival. Th e majority of these patients 
had chronic allograft  nephropathy with a glomerular 
component on biopsy compared to the normal com-
plement group who had normal biopsy fi ndings. Th ey 
also found that low complement was more common 
in the group with SLE who had WHO class IV diag-
nosed before transplant. Complement levels before 
transplantation had no impact on allograft  or patient 
survival (24). Our patient with lethal outcome had 
high anti-dsDNA and PRA before transplantation. 
Even though a high PRA is not considered a prog-
nostic factor for lethal outcome, we can speculate 
whether high level of antibodies induced immune re-
sponse while she received intensive immunosuppres-
sive protocol with Th ymoglobulin induction, plasma 
exchange before transplantation, and maintenance 
with tacrolimus, mycophenolate mofetil and steroids. 
Th e presence of antiphospholipid antibodies has been 
associated with an increased incidence of graft  vessel 
thrombosis and other thrombotic events in recipients. 
A study comparing SLE patients with a control group 
demonstrated thrombotic events in 17.4% and 5%, 
respectively. However, it seems that not all antibodies 
have the same predictive prognostic value. One study 
showed that β2 GPI antibodies, antiphosphatidyl ser-
ine/prothrombin antibodies and lupus antigen strong-
ly correlated with the increased risk of thrombosis, 
whereas anticardiolipin had a weaker association. In 
addition to thrombosis, bleeding was an increased 
problem, as well as antiphospholipid syndrome (APS) 
recurrence in the graft ed kidney. Outcome was com-
pared between 3 groups APS+, APS+/- and APS- with 
a fatal outcome in 33%, 16% and 3.4%, respectively; 
75% of the fatal outcomes in the APS+ group occurred 
within three months of transplantation. In four pa-
tients where effi  cient anticoagulation was instituted 
early post-transplant, three still experienced a major 
thrombotic event (25). Recent studies have confi rmed 
the negative impact of antiphospholipid antibodies 
on survival, but reveal that the pre-transplant histo-
ry of antiphospholipid syndrome has an even greater 
impact (26). Our result of 16.7% (n=2) incidence of a 
thrombotic event could suggest that some patients had 
antiphospholipid antibodies, although the screening 
prior to transplantation showed no signs of serological 
positivity. Also, a case of post-biopsy extensive bleed-
ing was recorded.
Recurrence of lupus nephritis (RLN) in the trans-
planted kidney has been investigated as a cause of the 
increased rate of graft  failure in SLE patients. Results 
have shown that the incidence is 1%-3%, but in studies 
of protocol biopsies, LN was found in as many as 43% 
(27). Most of these were WHO class I or II, which is 
clinically nonsignifi cant and did not have an impact 
on graft  outcome (28). Th e possible explanations for 
confl icting results in this question is that there is no 
consensus on the defi nition of disease recurrence, im-
munofl ourescence or electron microscope are not rou-
tinely used in diagnosis, and lastly because of the small 
number of patients that undergo follow up biopsy (29-
31). Two of our patients had RLN. One had lost his 
fi rst graft  due to RLN, and the other still has a func-
tioning graft . Our patient outcomes showed no clear 
correlation between age, previous transplantation or 
number of comorbidities. Episodes of acute rejection 
or RLN brought a higher risk of poor outcome. 
CONCLUSION 
Despite advances in the treatment of SLE, the inci-
dence of ESKD in this population is steadily increas-
ing. Most of the studies established KT as a far supe-
rior treatment option compared with dialysis, with a 
higher survival rate and lower rate of complications. 
Preemptive KT and the use of living kidney donors 
seem to further improve the outcomes, but only in 
patients with quiescent SLE activity. Nevertheless, pa-
tients with SLE tend to have an increased risk of graft  
rejection and mortality than other ESKD patients. 
As this can be explained by their immune status, we 
propose thorough pre-transplant evaluation of every 
SLE patient in order to ensure safe approach to KT. 
We also recommend carefully formed post-transplant 
follow up strategy. Although the incidence rates of 
RLN seem to be higher than previously thought, we 
do not recommend protocol biopsies as RLN mainly 
is of silent nature and does not require any change in 
the immunosuppressive regimen. However, new-on-
set proteinuria, increased serum creatinine, glo-
merular hematuria and low serum complement lev-
els should immediately raise suspicion of RLN and 
should be quickly recognized. In patients with APS, 
it is important to keep close immunological control 
since anticoagulant therapy is clearly not enough to 
prevent thrombotic events. While there are still many 
unanswered questions relating to the management of 
this immunologically very sensitive group of patients, 
forming a multidisciplinary transplantation team in-
cluding rheumatologists and nephrologists would en-
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able thorough evaluation of SLE patients with possible 
risk assessment and adjustment of follow up strategy 
to achieve an optimal survival outcome.
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Uvod i ciljevi: Transplantacija bubrega metoda je izbora u liječenju završnog stadija kronične bubrežne bolesti u bolesnika s 
lupusnim glomerulonefritisom (LN). Ipak, u usporedbi s drugim bolesnicima ova skupina unatoč napretku u liječenju i dalje 
pokazuje lošiji ishod. Glavni cilj ovog istraživanja bio je usporediti ishode našeg Centra s ishodima drugih studija te raspra-
viti nove mogućnosti u praćenju i liječenju ove skupine pacijenata. Ispitanici i metode: Svi istraživani parametri prikupljeni 
su iz dostupne medicinske dokumentacije. Rezultati: 12 bolesnika sa SLE, prosječne dobi 37 (18-56) godina, učinjena je 
transplantacija u našem Centru od veljače 2007. godine. Svi su bolesnici bili primatelji presatka kadaveričnog darivatelja. 
Najčešći komorbiditeti bile su kardiovaskularne bolesti. U vrijeme transplantacije 91,7% bolesnika bilo je u potpunoj se-
rološkoj i kliničkoj remisiji osnovne bolesti. Stupanj tkivne podudarnosti bio je zadovoljavajući, a uspostavljanje bubrežne 
funkcije promptno u svih ispitanika. Prosječno vrijeme preživljenja presatka iznosilo je 41 (0-93) mjesec. Kod 66,7% bole-
snika sa stabilnom bubrežnom funkcijom, to je vrijeme iznosilo 61 (22-93) mjesec, za tri je presatka zabilježeno preživljenje 
dulje od 5 godina. Tri su bolesnika graftektomirana (25%), dok je u jedne bolesnice zabilježen smrtni ishod. Gubitak pre-
sadaka nastupio je u ranom posttransplantacijskom razdoblju – od 0 do 5 mjeseci nakon transplantacije. Zaključak: Iako 
postoje brojna neistražena i neodgovorena pitanja vezana uz zbrinjavanje ove imunološki vrlo osjetljive i zahtjevne skupine 
bolesnika, pažljiva skrb prije i nakon transplantacije te uska suradnja nefrologa i imunologa omogućavaju dobar ishod uz 
značajno povećanje kvalitete života.
Ključne riječi: lupusni nefritis, transplantacija, ishod
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